A Sampling of Highlights from the Literature

What We're Reading| March 04 2024 A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors Author & Article Information Online ISSN: 2326-6074 Print ISSN: 2326-6066 ©2024 American Association for Cancer Research2024American Association for Cancer Research Cancer Immunol Res (2024) 12 (3): 281. https://doi.org/10.1158/2326-6066.CIR-12-3-WWR Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record March 4 2024 Citation A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors. Cancer Immunol Res 1 March 2024; 12 (3): 281. https://doi.org/10.1158/2326-6066.CIR-12-3-WWR Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Research identifies epigenetic and transcriptomic regulators of stemlike CD8+ CAR T-cell fate (Klem via Wikimedia Commons) How stemlike CD8+ chimeric antigen receptor (CAR) T-cell (Ts) differentiation to effector-like CD8+ CAR T cells (Teff) or terminally exhausted CD8+ CAR T cells (Tex) is regulated is not well understood. Through single-cell transcriptomic and epigenomic analyses, Zhu et al. show that each of these three CD8+ CAR T-cell subsets are defined by distinct transcription factors. Changes in chromatin accessibility precede transcriptional changes, priming a cell for regulation by the next set of transcription factors. FOXP1 limits Ts to Teff differentiation, whereas KLF2 promotes Teff differentiation and suppresses Tex differentiation. The data may provide new ways to manipulate CD8+ CAR T-cell differentiation for therapeutic benefit. Zhu Z, …, Wu T. Nat Immunol 2023 November 27;25:117–28. Pancreatic cancer... You do not currently have access to this content.